AZD0328

DRUG5 trials

Sponsors

AstraZeneca, King's College London

Conditions

Alzheimer's DiseaseHealthyHealthy VolunteersMild Cognitive ImpairmentParkinson DiseaseSchizophrenia

Phase 1

Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD0328 in Elderly Healthy Subjects

CompletedNCT00687141

AstraZenecaAlzheimer's Disease

Start: 2007-11-30End: 2008-06-30Updated: 2010-12-10

Safety, Tolerability & PK of AZD0328 in Caucasian & Japanese

CompletedNCT00738959

AstraZenecaHealthy Volunteers

Start: 2008-06-30End: 2008-10-31Updated: 2008-10-29

To Evaluate the Effect of Food on the Pharmacokinetics (PK) of AZD0328

CompletedNCT00752830

AstraZenecaHealthy

Start: 2008-09-30End: 2008-10-31Updated: 2008-10-29

Phase 2

Study to Asses Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of AZD0328 in Patients With Schizophrenia

TerminatedNCT00669903

AstraZenecaSchizophrenia

Start: 2008-04-30End: 2008-11-30Updated: 2010-08-06

Parkinson's Disease With Mild Cognitive Impairment Treated With Nicotinic Agonist Drug

WithdrawnNCT04810104

King's College LondonMild Cognitive Impairment, Parkinson Disease

Start: 2022-10-31End: 2024-04-30Updated: 2022-10-14